Efficacy and safety of PD‐1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study

BACKGROUND: Immunotherapy‐antiangiogenesis combination therapy has achieved excellent survival outcomes in hepatocellular carcinoma (HCC) in clinical trials. However, the combination therapy for HCC outside clinical trials is not well studied, and predictive factors are lacking. Here, we retrospecti...

Descripción completa

Detalles Bibliográficos
Autores principales: Yao, Junlin, Zhu, Xudong, Wu, Zhiheng, Wei, Qing, Cai, Yibo, Zheng, Yu, Hu, Xinyu, Hu, Hong, Zhang, Xiangyu, Pan, Hongming, Zhong, Xian, Han, Weidong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554456/
https://www.ncbi.nlm.nih.gov/pubmed/35403359
http://dx.doi.org/10.1002/cam4.4747

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9554456/
https://www.ncbi.nlm.nih.gov/pubmed/35403359
http://dx.doi.org/10.1002/cam4.4747

Ejemplares similares